Patents by Inventor Charles Theuer
Charles Theuer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10195281Abstract: The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.Type: GrantFiled: September 5, 2013Date of Patent: February 5, 2019Assignee: Tracon Pharmaceuticals, Inc.Inventors: Suzanne Benedict, Mark Cornell Manning, Brian M. Murphy, Sharon Real, Charles Theuer
-
Publication number: 20190016815Abstract: The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.Type: ApplicationFiled: October 1, 2018Publication date: January 17, 2019Inventor: Charles Theuer
-
Patent number: 10155820Abstract: The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.Type: GrantFiled: November 11, 2015Date of Patent: December 18, 2018Assignee: TRACON PHARMACEUTICALS, INC.Inventor: Charles Theuer
-
Publication number: 20180311359Abstract: The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.Type: ApplicationFiled: July 13, 2018Publication date: November 1, 2018Inventors: Suzanne Benedict, Mark Cornell Manning, Brian M. Murphy, Sharon Real, Charles Theuer
-
Patent number: 9944714Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: GrantFiled: October 28, 2016Date of Patent: April 17, 2018Assignee: TRACON PHARMACEUTICALS, INC.Inventors: Charles Theuer, Maximiliano Vasquez
-
Patent number: 9926375Abstract: The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.Type: GrantFiled: April 18, 2016Date of Patent: March 27, 2018Assignee: TRACON PHARMACEUTICALS, INC.Inventor: Charles Theuer
-
Publication number: 20170335005Abstract: The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.Type: ApplicationFiled: November 11, 2015Publication date: November 23, 2017Inventor: Charles Theuer
-
Publication number: 20170312233Abstract: Provided herein are pharmaceutical compositions and methods of treating cancer wherein the cytotoxic activity of an anticancer agent is potentiated by the combination of base excision repair (BER) pathway inhibitors.Type: ApplicationFiled: July 12, 2017Publication date: November 2, 2017Inventor: Charles Theuer
-
Publication number: 20170044267Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: ApplicationFiled: October 28, 2016Publication date: February 16, 2017Inventors: Charles Theuer, Maximiliano Vasquez
-
Patent number: 9518122Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: GrantFiled: August 27, 2015Date of Patent: December 13, 2016Assignee: Tracon Pharmaceuticals, Inc.Inventors: Charles Theuer, Maximiliano Vasquez
-
Publication number: 20160257755Abstract: The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.Type: ApplicationFiled: April 18, 2016Publication date: September 8, 2016Inventor: Charles Theuer
-
Publication number: 20160009811Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: ApplicationFiled: August 27, 2015Publication date: January 14, 2016Inventors: Charles Theuer, Maximilliano Vasquez
-
Patent number: 9150652Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: GrantFiled: October 15, 2013Date of Patent: October 6, 2015Assignee: Tracon Pharmaceuticals, Inc.Inventors: Charles Theuer, Maximiliano Vasquez
-
Publication number: 20150209430Abstract: The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.Type: ApplicationFiled: September 5, 2013Publication date: July 30, 2015Applicant: Tracon Pharmaceuticals, Inc.Inventors: Suzanne Benedict, Mark Cornell Manning, Brian M. Murphy, Sharon Real, Charles Theuer
-
Publication number: 20140314742Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: ApplicationFiled: October 15, 2013Publication date: October 23, 2014Applicant: TRACON PHARMACEUTICALS, INC.Inventors: Charles Theuer, Maximiliano Vasquez
-
Patent number: 8609094Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: GrantFiled: May 31, 2012Date of Patent: December 17, 2013Assignee: Tracon Pharmaceuticals, Inc.Inventors: Charles Theuer, Maximiliano Vasquez
-
Publication number: 20130030237Abstract: Provided herein are pharmaceutical compositions and methods of treating cancer wherein the cytotoxic activity of an anticancer agent is potentiated by the combination of base excision repair (BER) pathway inhibitors.Type: ApplicationFiled: April 15, 2011Publication date: January 31, 2013Inventor: Charles Theuer
-
Publication number: 20120294864Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: ApplicationFiled: May 31, 2012Publication date: November 22, 2012Applicant: TRACON PHARMACEUTICALS, INC.Inventors: Charles Theuer, Maximiliano Vasquez
-
Patent number: 8221753Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: GrantFiled: March 31, 2010Date of Patent: July 17, 2012Assignee: Tracon Pharmaceuticals, Inc.Inventors: Charles Theuer, Maximiliano Vasquez
-
Publication number: 20110076263Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: ApplicationFiled: March 31, 2010Publication date: March 31, 2011Applicant: TRACON PHARMACEUTICALS, INC.Inventors: Charles Theuer, Maximiliano Vasquez